Ly9 (CD229) Cell-Surface Receptor is Crucial for the Development of Spontaneous Autoantibody Production to Nuclear Antigens

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi:10.3389/fimmu.2013.00225</td>
</tr>
<tr>
<td>Citable link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:11855914">http://nrs.harvard.edu/urn-3:HUL.InstRepos:11855914</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>
Ly9 (CD229) cell-surface receptor is crucial for the development of spontaneous autoantibody production to nuclear antigens

Jose de Salort1, Marta Cuenca1, Cox Terhorst2, Pablo Engel1 and Xavier Romero1,3 *

1 Immunology Unit, Department of Cell Biology, Immunology and Neurosciences, Medical School, University of Barcelona, Barcelona, Spain
2 Division of Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
3 Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

INTRODUCTION
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by major immunological stigmata, the production of antibodies against own cellular components. The mechanisms underlying SLE are complex and include genetic, epigenetic, environmental, hormonal, and immunoregulatory factors. Furthermore, multiple pathogenic pathways likely contribute to end-organ damage in this heterogeneous disease (1–3). Elucidation of these pathways, as well as the identification of new molecular disease markers and targets that account for the pathogenesis of lupus, are crucial to improve currently available therapeutic approaches.

Genetic predisposition is a central factor to the development of SLE (4, 5). Both Genome Wide Association studies (GWAS) and the in depth analyses of genetically altered and congenic mice have provided insights into the genetic control of lupus. For instance, mouse strains bearing either a NZW- or 129-derived genomic segment that is embedded in chromosome 1 of B6 mice, develop a lupus-like disease due to the epistatic interactions between the 129-derived genes and B6 genes (6). Analysis of congenic NZW × B6 mice identified the Sle1 region of chromosome 1 and its subregions Sle1a, -b, and -c, as key elements involved in breaching B- and T-cell tolerance to chromatin, an essential early step leading to full-blown onset of the disease. Remarkably, multiple gene-wide linkage scans in SLE families have also identified a synergetic lupus susceptibility locus (region 1q23) in human chromosome 1 (7, 8).

Precise mapping of the Sle1 region identified a gene interval of 0.9 Mb, termed Sle1b, as the most potent segment involved in the generation of autoantibodies. Interestingly, this segment includes seven signaling lymphocyte activation molecule family (SLAMF) cell-surface receptor genes (9). The proteins encoded by these genes are the best suited candidates for controlling signaling pathways in Sle1 tolerance due to their extensive polymorphic nature and isoform diversity, coupled with their ability to modulate innate and adaptive immunity (10, 11). The SLAMF receptors (SLAMF1–9) are involved in the functional regulation of several immune cell types, including helper and cytotoxic T lymphocytes, NK cells, and macrophages (12–15). These receptors mediate adhesion and regulate cognate T-cell–B-cell interactions, which elicit signal transduction by recruiting SLAM-associated protein (SAP). Importantly, SAP deficiency selectively impairs the ability of CD4+ T cells to stably interact with cognate B cells, avoiding differentiation toward T follicular helper cells (Tfh) as well as germinal center (GC) B cells. More importantly, in vitro functional experiments showed that Ly9 acts as an inhibitory receptor of IFN-γ producing CD4+ T cells. Taken together, our findings reveal that the Ly9 receptor triggers cell intrinsic safeguarding mechanisms to prevent a breach of tolerance, emerging as a new non-redundant inhibitory cell-surface receptor capable of disabling autoantibody responses.

Keywords: SLAMF, Ly9 (CD229, SLAMF3), anti-DNA autoantibodies, disease susceptibility, systemic lupus erythematosus, murine Lupus
detected in lupus patients and lupus-prone mice had suffered isotype switching and somatic hypermutation, which facilitated the binding to self-antigens with high affinity, all indicating the involvement of GC pathways in this disease (21, 22). This, therefore, provides a rationale for determining not only the exact role played by SLAMF receptors as key drivers of Th and GC formation, but also their potential as appealing therapeutic targets for autoantibody-mediated diseases.

While recent reports have identified Slamf6 (Ly108) receptor and its isoforms and Slamf2 (284) as contributing to the role played by Sle1b in tolerance (23–25), the involvement of other SLAMF members cannot be excluded. Of particular interest is the Ly9 (CD229, Slamf3) molecule, since a comparative analysis between B6 and the autoimmune congenic strain B6.Sle1b revealed significant differences in its isoforms usage, as well as in the extent of polymorphisms and expression levels (9), with the evidence indicating the possible participation of Ly9 in B6.Sle1b autoimmunity. Briefly, Ly9 expression is restricted to hematopoietic cells, including B and T lymphocytes (26). As has been shown in other SLAMF members, Ly9 functions as a homophilic adhesion receptor and its cytoplasmic tail contains two copies of the conserved tyrosine-based switch motif (ITSM), which is a docking site for the adapter molecules SAP and EAT-2 (27, 28). Ly9-deficient mice with a mixed 129 x B6 background exhibited no major T-cell developmental abnormalities and only very mild defects in T-cell responses (29). Recent findings demonstrate the role of Ly9 as a unique inhibitory cell-surface receptor regulating the size of the thymic innate CD8+ T-cell pool and the development of invariant Natural Killer T (iNKT) cells (30). Nonetheless, the functional role of Ly9 in lupus pathogenesis remains unknown. Here, we use Ly9-deficient mice, which were generated with 129-derived ES cells and then backcrossed onto B6 or BALB/c backgrounds, in order to determine the role of the Ly9 receptor in autoantibody development.

MATERIALS AND METHODS

MICE

Ly9−/− mice (129 x B6), generously provided by Dr. McKean (29), were backcrossed onto BALB/c background for 12 generations to generate the Ly9−/− (BALB/c.129) strain and onto C57BL/6 (B6) background for 12 generations to generate the Ly9−/− (B6.129) strain. Eight-week-old BALB/c and B6 wild-type mice were purchased from Charles River Laboratories (Saint-Aubin-lès-Elbeuf, France). All mice strains were maintained under specific pathogen-free (SPF) conditions for up to 12 months. Serum samples were obtained in compliance with institutional guidelines as well as with national laws and policies. At 12 months, mice were euthanized, a peritoneal lavage was carried out, and peritoneal cells were harvested. Experiments were conducted in compliance with institutional guidelines as well as with national laws and policies.

ANTI-NUCLEAR ANTIBODIES ANALYSIS

Anti-nuclear antibodies (ANA) titers were determined by indirect immunofluorescence using permeabilized Hep-2 cells. Serum samples were progressively diluted and incubated for 1 h at room temperature on Hep-2 cells followed by Texas Red-conjugated anti-mouse IgG (Jackson Laboratory, Bar Harbor). After washing, the nucleus was stained with 4,6-diamidino-2-phenylindole (DAPI). Analysis was performed by fluorescence detection using a Nikon Eclipse fluorescent microscope (Nikon, Tokyo).

ANTI-DOUBLE-STRANDED DNA AND ANTI-CHROMATIN DETECTION

ELISA assays were performed to quantify levels of anti-double-stranded DNA (anti-dsDNA) and anti-chromatin antibodies in sera of mice. For anti-dsDNA detection, an ELISA was carried out using heat-denatured calf thymus DNA (Sigma Chemical Co., St Louis, MO, USA). dsDNA was coated onto 96-well plates (Corning Costar, Corning, NY, USA) at 10 µg/ml. Purified antibody anti-dsDNA (Clone HpS22, Immunotools, Friesoythe, Germany), used as standard, was serially diluted. Standards and test serums (dilution 1:100) were incubated on plates for 1 h at room temperature. After extensive washing, autoantibodies were detected using a HRP-conjugated anti-mouse IgG (Sigma-Aldrich) and developed with OPD substrate (Sigma-Aldrich).

Anti-chromatin autoantibodies were detected using nucleosome antigen (Arotec Diagnostics Limited, Wellington, New Zealand). The nucleosome antigen was coated on 96-well plates at 3 µg/ml. Serums were diluted 1:100 and incubated for 1 h at room temperature. Autoantibodies against nucleosome were detected using a HRP-conjugated anti-mouse IgG and developed with substrate. All samples were handled simultaneously under the same experimental conditions and results are expressed as OD values.

IgG ISO TYPE DETECTION

Basal serum IgG isotypes were determined by ELISA using purified goat anti-mouse IgG (Sigma-Aldrich) coated 96-well plates. 1:100 diluted mouse serums were incubated for 1 h at room temperature. After extensive washing, IgG isotypes were detected using biotin-conjugated anti-mouse IgG1, IgG2a, IgG2b, and IgG3 (Jackson Laboratory). All samples were handled simultaneously under the same experimental conditions and results are expressed as OD values.

FLOW CYTOMETRY

Single-cell suspensions were incubated with 20% heat-inactivated rabbit serum before being stained on ice with fluorophore-labeled antibodies against surface molecules using standard methods. Data was acquired using a FACScanto II (BD Pharmingen, San Jose, CA, USA) flow cytometer and analyzed with either FACSdivaTM (BD Pharmingen) or FlowJo software (Tree Star, San Carlos, CA, USA). The following anti-mouse mAbs were obtained from BD Pharmingen: CD4-FITC, CD11b-PE, CD21-FITC, CD23-FITC, CD24-FITC, CD43-FITC, CD44-FITC, CD62L-FITC, CD69-FITC, CD154-PE, c-Kit-PE, Ter-119-PE, IgM-biotinylated, and CXCR5-biotinylated. The mAbs CD8-FITC, CD11b-FITC, CD25-PE, CD25-FITC, IgM-FITC, B220-FITC, as well as the isotype-matched control Abs, were acquired from ImmunoTools (Friesoythe, Germany). The following mAbs were obtained from BioLegend (San Diego, CA, USA): CD3-FITC, CD4-Pacific Blue, CD8-PE-Cy5, PD1-PE, PD1-PE-Cy7, B220-Pacific Blue, CD41-FITC, and IgD-APC-Cy7. The mAbs CD3-APC, CD5 PE-Cy7, CD229-APC, Sca-1-APC, and GL-7-FITC were purchased from eBioscience (San Diego, CA, USA). Anti-mouse CD138-APC was obtained from R&D Biosystems.
Ly9 receptor mitigates autoimmune responses

Ly9-DEFICIENT MICE DEVELOP SPONTANEOUS AUTOIMMUNITY

To assess the role of Ly9 in humoral autoimmune responses, Ly9-deficient mice were generated by mutated 129-derived ES cells (29) and backcrossed with B6 (C57BL/6) or BALB/c mice for 12 generations. First, we analyzed the presence of ANA in sera of 3, 6, 9, and 12 months old Ly9−/− (B6.129) mice by immunofluorescence staining of Hep-2 cells. As shown in Figures 1A,B, an age-associated increase in ANA titers was detected in Ly9−/− (B6.129) mice that was significantly higher than those of their age-matched Ly9+/− (wild-type; wt) counterparts. The differences in ANA serum levels between wt and Ly9−/− (B6.129) mice were statistically significant as early as 3 months of age. At 12 months of age, 80% of the serum samples from Ly9−/− (B6.129) showed ANA titers ≥1:4096. In contrast, 100% of the serum titers from their wt counterparts measured ≤1:512. Further analysis demonstrated that by age 12 months Ly9−/− (B6.129) mice displayed significant increases in their circulating levels of anti-double-stranded (ds) DNA and anti-nucleosome IgG antibodies in comparison to their wt counterparts (Figures 1C,D).

In order to further dissect the role of Ly9 in the humoral autoimmune response, excluding any effects stemming from...
epistatic interactions, we determined autoantibodies in the serum of $\text{Ly9}^{-/-}$ (BALB/c.129) mice. Once again, an age-associated increase in ANA titers was also detected in $\text{Ly9}^{-/-}$ (BALB/c.129) mice that was significantly higher than those of their age-matched wt counterparts. As was observed in the B6 background mice, the differences in ANA serum levels between wt and $\text{Ly9}^{-/-}$ (BALB/c.129) mice were statistically significant as early as 3 months of age, reaching its highest level at age 12 months when 91.6% of $\text{Ly9}^{-/-}$ (BALB/c.129) mice presented ANA titers $\geq 1:256$ compared with 72.7% of their wt counterparts whose titers measured $\leq 1:64$ (Figures 2A,B). Notably, ANA titers in $\text{Ly9}^{-/-}$ (B6.129) mice were always higher than those of $\text{Ly9}^{-/-}$ (BALB/c.129) at the evaluated time points, most likely due to the additional effect of the epistatic interactions, which induced spontaneous loss of immune tolerance to nuclear antigens (25). Comparable levels of anti-dsDNA and anti-nucleosome were detected on $\text{Ly9}$-deficient mice from both genetic backgrounds (Figures 2C,D and Figures 1C,D), although $\text{Ly9}^{-/-}$ (B6.129) mice displayed much higher ANA titers. This likely reflects the presence of preferential nuclear antigen recognition based on genetic background, which has been also observed in other lupus models (31).

$\text{Ly9}$-deficient mice exhibited a significant increase in IgG2b (Figure 3A) as well as higher ratios of IgG2a, 2b, and IgG3 isotypes vs. IgG1 than wt mice. Due to the high titers of autoantibodies observed on aged $\text{Ly9}$-deficient mice sera, we further investigated the presence of alterations in these animals’ renal physiology and functionality. Twelve-month-old $\text{Ly9}^{-/-}$ (BALB/c.129) mice did not exhibit proteinuria (Figure 3B) or differences in their glomeruli morphology compared to their wt counterparts. Although we observed a mild increase in IgG-immunocomplex deposits in $\text{Ly9}$-deficient mice (Figure 3C), this initial trait prior to any sign of glomerulonephritis did not trigger a renal pathology.

In summary, our findings reveal that the absence of the $\text{Ly9}$ receptor per se initiates the progressive development of autoantibodies, independently of any epistatic interactions.
Ly9−/− AGED MICE EXHIBITED SPLENOMEGALY AND ALTERED KEY CELL SUBSETS RELATED TO SELF-TOLERANCE

The role of Ly9 as an inhibitor molecule in the development of spontaneous autoimmunity, excluding any effects dictated by epistatic interactions, is further supported by the observation that 12-month-old Ly9−/− (BALB/c.129) mice exhibited splenomegaly, which is a feature often present in SLE-prone mice (32, 33). The mean and SEM of spleen weight in wt (n = 7) and Ly9−/− (BALB/c.129) mice (n = 11) were 95.53 ± 3.40 and 147.7 ± 10.36 mg, respectively (p = 0.0021). Consistently, an increase of 75.8% in Ly9−/− (BALB/c.129) spleen cell numbers, compared with wt spleens, was observed (Figures 4A,B).

A deeper analysis of cell subsets by flow cytometry demonstrated altered B- and T-cell peripheral homeostasis in Ly9-deficient mice. We first inspected the B-cell signature of the disease in 12-month-old Ly9−/− (BALB/c.129) mice (Table 1). Notably, the most significant difference was found in GC B cells, with a percentage of 0.64 ± 0.19 in wt and 1.28 ± 0.30 in Ly9-deficient mice (p = 0.0004), which was also evident due the striking expansion of GC cell numbers (Figure 4C and Table 1).

Although a major percentage of GC was observed in Ly9-deficient mice, only a slight decrease in the percentage of follicular B cells was detected: 88.39 ± 3.15 (Ly9+/+) and 78.01 ± 7.25 (Ly9−/−), which is indicative of follicular B-cell areas with a major proportion of GC B cells. Transitional 1 (T1) B cells in wt and Ly9−/− (BALB/c.129) mice showed percentages of 4.48 ± 1.08 and 9.47 ± 3.12, respectively. Marginal zone (MZ) B cells from Ly9-deficient mice also showed increased percentages: 4.54 ± 1.78.
suggested that the peripheral tolerance checkpoint that controls GC and Tfh cells becomes altered by the absence of Ly9 molecule (Figure 3A). In the Ly9-deficient spleen, we found a slight increase in the ratios occurring between CD4+ and CD8+ T cells. We also observed an increase in effector CD4+ and CD8+ T-cell subsets, although it was not significant. Interestingly, the nKT cell pools in these animals were also enlarged: 3.53 ± 1.23% wt and 7.67 ± 2.80% Ly9−/− mice (Table 1).

We conclude that Ly9 gene ablation in a BALB/c background results in the disturbance of B and T cell subsets involved in autoimmunity, with major differences occurring in both Tfh cells and GC B cells.

**Ly9 RECEPTOR MODULATES IFN-γ SECRETION BY CD4+ T CELLS**

To determine the lymphocyte subsets that facilitate the ignition of SLE-related pathology in the absence of Ly9, we searched for any altered peripheral cell populations in 8- to 12-week-old Ly9−/− (BALB/c.129) mice. Slight differences were observed in the T-splenic compartment with a small increase in percentage of CD4+ T and inNKT. Notably, most of the alterations were displayed by B-cell subsets, with Transitional T1 B cells presenting the major difference (Table 2). A deeper examination of T1 and MZ B cells including IgM as a cell marker (T1:CD23− CD21+ IgM+, MZ: CD23+ CD21+ IgM+) (37) demonstrates that Ly9-deficient mice possessed approximately a threefold increase of T1 subset and also an expanded MZ B subset (Figure S1 in Supplementary Material). Based on these results, we conclude that Ly9-deficiency alters the development of B-cell subsets which may be involved in the generation of autoantibodies.

Abnormalities in BCR signaling could shape the splenic B-cell populations and predispose to autoimmune disease. Therefore, we assessed the proliferation and survival of splenic B cell from Ly9−/− mice after IgM stimulation. The proliferation and apoptotic responses of Ly9-deficient B cells were similar to those observed in the wt B cells, with the exception of a slight decrease in percentage of late apoptotic cells in the Ly9-deficient mice (Figure 5).

Since earlier studies have demonstrate the critical implication of SLAM receptors in Th1/Th2/Th17 polarization (14, 26, 38), we hypothesized that Ly9-deficient splenocytes in 8- to 12-week-old mice would foster an alteration in T-cell cytokine production prior to disease onset, thereby enabling autoantibody production at older ages. First, we asked whether the ablation of murine Ly9 could modulate IL-17 secretion by CD4+ T cells under Th17 polarizing conditions, since earlier reports have implicated the human Ly9 receptor in IL-17 T-cell secretion (38, 39). No significant differences were detected in the percentage of IL-17 secreting CD4+ T cells (Figure 6A). On the other hand, our group has previously shown that monoclonal antibodies against Ly9 negatively regulate TCR signaling, thereby inhibiting ERK phosphorylation and IFN-γ secretion (26, 40). Herein, we investigated the role of Ly9 in IFN-γ modulation by activating splenic T cells with anti-CD3 and anti-CD28. A significant increase in IFN-γ secretion, as well as an increase in the expression of CD40L in CD4+ T cells was detected in the absence of Ly9 compared with wt cells (Figures 6B,C). A similar result was obtained when evaluating the expression of the CD25 activation marker (data not shown). In
addition, PMA/ionomycin activation of splenic cells revealed that Ly9-deficient mice foster CD4+ T, CD8+ T, and iNKT cells capable of secreting major quantities of IFN-γ prior to the development of autoimmunity (Figure 6D). Furthermore, isolated Ly9-deficient CD4+ T cells consistently showed an increased IFN-γ production after PMA/ionomycin activation as compared with wt mice (Figure 6E). In contrast, no significant difference in percentage of IL-4 producing CD4+ T cells was observed (data not shown). In accordance with these results, 12-month-old Ly9−/− (BALB/c.129) mice exhibited an increased percentage of IFN-γ producing CD4+ T cells, which correlated with the high ANA titers detected in serum (Figure 6F). Nevertheless, we could not detect IFN-γ in the serum of these mice (data not shown).

Thus, in the absence of the Ly9 molecule occurs an increase in peripheral T and iNKT IFN-γ secretion, a key cytokine in the pathogenesis of SLE which has been previously shown to trigger the accumulation of pathogenic Th and GC B cells (41).

**DISCUSSION**

Despite extensive research, the mechanisms by which susceptibility and effector genes initiate and promote autoantibody production and tissue damage remain poorly defined. In the present study, we have shown that Ly9 deficiency results in a spontaneous loss of tolerance, reflected principally in the development of autoantibodies, a process which is thought to underlie the initiation of SLE syndrome.

We first found that the absence of the Ly9 gene in mice with a B6 and BALB/c background resulted in the development of autoantibodies. The loss of tolerance to nuclear antigens detected in Ly9−/− (B6.129) mice was reminiscent of those previously observed in B6.Sle1 and B6.129Chr1b congenic mouse strains (6, 42). We found that Ly9−/− (B6.129) mice developed autoantibodies as early as 12 weeks of age. In fact, by 9 months of age all mice were autoantibody positive, a pattern similar to previously observed in B6.Sle1b and B6.129Chr1b congenic mouse strains (6, 42). We found that Ly9−/− (B6.129) mice developed autoantibodies as early as 12 weeks of age. In fact, by 9 months of age all mice were autoantibody positive, a pattern similar to previously observed in B6.Sle1b and B6.129Chr1b congenic mouse strains (6, 42). We found that Ly9−/− (B6.129) mice developed autoantibodies as early as 12 weeks of age. In fact, by 9 months of age all mice were autoantibody positive, a pattern similar to previously observed in B6.Sle1b and B6.129Chr1b congenic mouse strains (6, 42). We found that Ly9−/− (B6.129) mice developed autoantibodies as early as 12 weeks of age. In fact, by 9 months of age all mice were autoantibody positive, a pattern similar to previously observed in B6.Sle1b and B6.129Chr1b congenic mouse strains (6, 42).
We next assessed the role of Ly9 in autoimmune disease without the confounding influence of mixed haplotypes by utilizing Ly9<sup>−/-</sup> (BALB/c.129) mice. Although autoantibody titers were lower compared to Ly9<sup>−/-</sup> (B6.129) mice, this strain clearly developed an autoimmune response based on the significant increases of ANA, anti-dsDNA, and anti-chromatin antibodies compared to their wt counterparts. By contrast, other SLAMF receptor-deficiencies embedded in the BALB/c genome, such as Slamf1<sup>−/-</sup> (BALB/c.129) and Slamf2<sup>−/-</sup> (BALB/c.129), do not develop any autoimmune response (25), underscoring the role played by Ly9 as a negative regulator in the pathogenesis of lupus. Consequently, among the various SLAMF receptors, both Ly9 and 2B4 rise as unique factors contributing to the reinforcement of tolerance (24).

As a consequence of breaching tolerance, a plethora of disorders can develop <i>a posteriori</i>; e.g., T and B cells are reportedly involved in the amplification and perpetuation of the autoimmune response, resulting in inflammation and cytokine dysregulation (45). This proved to be the case in our 12-month-old Ly9-deficient mice in which various B and T cells subsets underwent alterations. Notably, the most noteworthy differences in older mice were found in Tfh and GC B cells, two cell types which have been shown to preferentially express the Ly9 receptor (46).

In order to begin to understand why Ly9-deficient mice developed spontaneous autoimmunity, we search for any abnormal peripheral B and T cell development prior to full autoantibody disorder on 8- to 12-week-old Ly9-deficient mice. We observed alterations in the B-cell splenic compartment, with the most prominent expansion displayed by Ly9-deficient transitional T1 B cells. Interestingly, SLE patients present increased numbers of T1 cells, although their role in lupus is still ill defined (35). In addition, 8- to 12-week-old Ly9-deficient mice displayed an increase in MZ B cells. Even though many autoreactive antibodies appear to be the product of GC reactions, major evidence begins to reveal that MZ B cells play a key role in homeostasis and tolerance. Notably, the MZ B-cell expansion has been directly implicated in lupus pathogenesis in some murine models (47–50), but not others (51, 52). Autoimmunity mediated by B cell is usually linked to a B-cell hyperresponsiveness upon BCR stimulation, change B-cell subsets normal architecture, and culminates in a systemic autoimmune disease (53). Here, we show that there’s similar proliferation and survival of Ly9-deficient B cells as compared with wt cells, although we can not exclude the abnormal function of particular B-cell subsets in the Ly9-deficient mice which could be the subject of future investigations.

Next, we investigated how the absence of Ly9 could possibly contribute to a cytokine imbalance prior to disease onset. Others have shown that the engagement of human naive CD4<sup>+</sup> T lymphocytes with an anti-human Ly9 monoclonal antibody

### Table 2 | Flow cytometry analysis of B- and T-splenic cell subsets from 8- to 12-week-old wt and Ly9<sup>−/-</sup> (BALB/c.129) mice.

<table>
<thead>
<tr>
<th>Parental Subset</th>
<th>Marker</th>
<th>Ly9&lt;sup&gt;+/+&lt;/sup&gt; Mean ± SD</th>
<th>Ly9&lt;sup&gt;−/-&lt;/sup&gt; Mean ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>B-CELL LINEAGE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B220&lt;sup&gt;+&lt;/sup&gt; T1</td>
<td>B220&lt;sup&gt;+&lt;/sup&gt;CD21&lt;sup&gt;-&lt;/sup&gt;CD23&lt;sup&gt;−&lt;/sup&gt; low</td>
<td>10.87 ± 0.71 ***</td>
<td>15.18 ± 0.46</td>
</tr>
<tr>
<td>Follicular-B</td>
<td>B220&lt;sup&gt;+&lt;/sup&gt;CD21&lt;sup&gt;+&lt;/sup&gt;CD23&lt;sup&gt;high&lt;/sup&gt;</td>
<td>79.96 ± 0.84 ***</td>
<td>74.30 ± 0.18</td>
</tr>
<tr>
<td>MZ-B</td>
<td>B220&lt;sup&gt;+&lt;/sup&gt;CD21&lt;sup&gt;+&lt;/sup&gt;CD23&lt;sup&gt;−&lt;/sup&gt; low</td>
<td>4.76 ± 0.21</td>
<td>5.79 ± 0.31</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>GC B cells</td>
<td>B220&lt;sup&gt;+&lt;/sup&gt;GL7&lt;sup&gt;+&lt;/sup&gt;</td>
<td>4.65 ± 0.65</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>Plasma B cells</td>
<td>B220&lt;sup&gt;−&lt;/sup&gt;CD138&lt;sup&gt;+&lt;/sup&gt;</td>
<td>0.27 ± 0.06</td>
</tr>
<tr>
<td><strong>T-AND NK-CELL LINEAGE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD3&lt;sup&gt;+&lt;/sup&gt;</td>
<td>CD4 SP</td>
<td>CD4&lt;sup&gt;+&lt;/sup&gt;CD8&lt;sup&gt;−&lt;/sup&gt;</td>
<td>65.93 ± 6.27</td>
</tr>
<tr>
<td>CD4&lt;sup&gt;+&lt;/sup&gt;</td>
<td>Effector CD4</td>
<td>CD3&lt;sup&gt;+&lt;/sup&gt;CD4&lt;sup&gt;+&lt;/sup&gt;CD8&lt;sup&gt;−&lt;/sup&gt;CD44&lt;sup&gt;high&lt;/sup&gt;CD62L&lt;sup&gt;low&lt;/sup&gt;</td>
<td>28.58 ± 1.66</td>
</tr>
<tr>
<td>CD8&lt;sup&gt;+&lt;/sup&gt;</td>
<td>Effector CD8</td>
<td>CD3&lt;sup&gt;+&lt;/sup&gt;CD8&lt;sup&gt;+&lt;/sup&gt;CD4&lt;sup&gt;−&lt;/sup&gt;CD44&lt;sup&gt;high&lt;/sup&gt;CD62L&lt;sup&gt;low&lt;/sup&gt;</td>
<td>75.0 ± 2.80</td>
</tr>
<tr>
<td>CD4&lt;sup&gt;+&lt;/sup&gt;</td>
<td>Reg T cells</td>
<td>CD3&lt;sup&gt;+&lt;/sup&gt;CD4&lt;sup&gt;+&lt;/sup&gt;CD25&lt;sup&gt;+&lt;/sup&gt;</td>
<td>8.77 ± 1.22</td>
</tr>
<tr>
<td></td>
<td>Tfh</td>
<td>CD3&lt;sup&gt;+&lt;/sup&gt;CD4&lt;sup&gt;+&lt;/sup&gt;PD1&lt;sup&gt;+&lt;/sup&gt;</td>
<td>3.40 ± 0.44</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CXC5&lt;sup&gt;+&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>iNKT</td>
<td>B220&lt;sup&gt;−&lt;/sup&gt;CD3&lt;sup&gt;+&lt;/sup&gt;CD1d Tet&lt;sup&gt;+&lt;/sup&gt;</td>
<td>4.22 ± 0.53</td>
</tr>
<tr>
<td>CD3&lt;sup&gt;+&lt;/sup&gt;</td>
<td>NK</td>
<td>CD3&lt;sup&gt;+&lt;/sup&gt;DX5&lt;sup&gt;+&lt;/sup&gt;</td>
<td>0.82 ± 0.32</td>
</tr>
</tbody>
</table>

T1, transitional 1 B cells; MZ-B, marginal zone B cells; GC B, germinal center B cells; SP, single positive; Reg, regulatory; Tfh, follicular helper T cells; iNKT, invariant natural killer T cells; NK, natural killer; p-value significance; *p < 0.05, **p < 0.001, ***p < 0.0001. Results represent the mean ± SEM of wt and Ly9<sup>−/-</sup> (BALB/c.129) mice (n = 5) for each subset analyzed.
under Th17 polarizing conditions results in an increase in IL-17 (38, 39). No alterations in IL-17 producing T lymphocytes were observed once Ly9-deficient mice splenic cells were activated under Th17 polarizing conditions. Previous reports showed a diminishing IL-4 production and no altered IFN-γ secretion by Ly9-deficient CD4 T cells (29). In contrast, in the absence of Ly9, we observed an increase in IFN-γ producing T cells with no significant alteration in IL-4 secretion. Importantly, IFN-γ has long been associated with lupus (54). This apparent contradiction could be explained by the influence of epistatic interactions as well as the mice background, since previous studies were performed in Ly9−/− with a mixed background (B6 × 129) mice. Recent reports have demonstrated that the overproduction of IFN-γ induces an aberrant accumulation of Tfh and GC cells (41). We also found that these subsets underwent expansion in Ly9−/− mice, when the influence of confounding epistatic interactions was absent. These observations suggest that the Ly9 molecule may play an inhibitory role in the expansion of these subsets. In addition, Ly9−/− mice showed a skewed isotype switching toward IgG2a/b, an isotype induced by a Th1 response that requires T cell-stimulated B lymphocytes. Although IgG2a antibodies are the most pathogenic class of immunoglobulin (55,
Ly9 receptor mitigates autoimmune responses

ACKNOWLEDGMENTS

Jose de Salort performed most of the experiments and analyzed the data; Marta Cuenca performed the B-cell functional experiments; Pablo Engel and Xavier Romero designed the experiments and supervised the study; Jose de Salort, Pablo Engel, and Xavier Romero wrote the manuscript; Cox Terhorst provided input into the conceptual development of the experiments and edited the manuscript. We thank Adriana Lázaro for technical assistance. We also thank the NIH Tetramer Core Facility for providing R-PE labeled murine CD1d tetramer pre-loaded with PBSS7. This work was supported by the Ministerio de Educación y Ciencia through Grants SAF 2009-07071/SAF 2012-39536 (to Pablo Engel) and by a grant from the NIH (2P01AI65687-06A1 to Pablo Engel and Cox Terhorst). Jose de Salort was supported by Ayuda Personal Investigador en Formación (APIF), a grant from the Universitat de Barcelona. Marta Cuenca was supported by Ministerio de Educación, Cultura y Deporte (AP2010-1754). Xavier Romero was supported by Beatriz de Pinós (2010 BP-B).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at http://www.frontiersin.org/Inflammation/10.3389/fimmu.2013. 00225/abstract

Figure S1 | Splenic T1 and MZ cells are expanded in Ly9−/− (BALB/c)129 mice. (A) Splenic lymphocytes from 8- to 12-week-old wt (n = 5) and Ly9−/− (B6:129) mice (n = 5) were stained using CD23, CD21, and IgM. (A) Representative dot plots from wt and Ly9−/− splenic cells. The gating strategy to characterize transitional and marginal zone (MZ) B cells is shown. (B) Quantitative analysis of the CD23+ percentage of MZ and Transitional 1 (T1) B cells as well as (C) MZ and T1-B cells periphery are shown. SEM and statistical significances are shown.

REFERENCES


Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 15 May 2013; paper pending published: 05 June 2013; accepted: 18 July 2013; published online: 31 July 2013.


This article was submitted to Frontiers in Inflammation, a specialty of Frontiers in Immunology.

Copyright © 2013 de Salort, Cuenca, Terhorst, Engel and Romero. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.